Bone immunity represents a dynamic interface where skeletal homeostasis intersects with systemic immune regulation. We synthesize emerging paradigms by contrasting two functionally distinct microenvironments: the marrow cavity, a hematopoietic and immune cell reservoir, and cancellous bone, a metabolically active hub orchestrating osteoimmune interactions. The marrow cavity not only generates innate and adaptive immune cells but also preserves long-term immune memory through stromal-derived chemokines and survival factors, while cancellous bone regulates bone remodeling via macrophage-osteoclast crosstalk and cytokine gradients. Breakthroughs in lymphatic vasculature identification challenge traditional views, revealing cortical and lymphatic networks in cancellous bone that mediate immune surveillance and pathological processes such as cancer metastasis.

The study of gene expression regulation systems, transcriptional, post-transcriptional, and translational processes require in-depth knowledge of the structure and dynamics of protein–DNA and protein–RNA complexes. Furthermore, the discovery of the multiple roles played by different types of RNA, including within extracellular vesicles, has raised new questions about the systems responsible for stabilizing and transporting these RNAs. Over the years, numerous experimental approaches have been developed for the study of complexes between proteins and nucleic acids, both in terms of the type and degree of accuracy of the information they are able to provide. Furthermore, some techniques have proven suitable for monitoring dynamic processes, while others provide very high-resolution data.

Can humans regrow limbs? Researchers find SP6 and SP8 genes are vital for regeneration in axolotls and mice, creating a viral gene therapy that mimics salamander regrowth powers.

Systemic therapy targets in mesothelioma.

Recent changes to clinical practice have made modest improvements in 1– 2-year survival, but longer-term survival remains unchanged, and durable benefit is very rare.

Combining immunotherapy with chemotherapy, particularly with novel bispecific agents, may result in more therapeutic modalities being administered together in the first-line setting. The current evidence for second-line treatments is sparse.

New targeted-therapy strategies are promising. Early-phase clinical trials are showing signals of efficacy in mesotheliomas harboring MTAP loss or inactivation of the Hippo pathway.

Further studies will be needed to robustly confirm clinical benefit. sciencenewshighlights ScienceMission https://sciencemission.com/Mesothelioma

---

Mesothelioma is a rare cancer that has seen few incremental improvements in survival over the past two decades. However, a significantly improved understanding of the underlying biology has led to new therapeutic advances with the potential to improve clinical outcomes. In this review, we take a snapshot of the current systemic therapy research landscape, with our goal to forecast the trajectory of drug development for mesothelioma over the next half-decade. In our current census, we identify 106 active trials including systemic therapies: 20 (19%) are molecularly targeted, 26 (25%) include immunomodulation, and 12 (11%) combining immunotherapy with antiangiogenic therapies. Collectively, the landscape of therapeutic innovation for mesothelioma is expanding, bringing hope that improvements in life expectancy may follow.